New Delhi [India], October 12 (ANI): Subject Expert Committee (SEC) has given a recommendation to the Drugs Controller General of India (DCGI) for the use of Bharat Biotech's COVID-19 vaccine Covaxin for the beneficiaries aged between 2-18 years, the official sources said.

Earlier, Dr Sanjay K Rai, a professor at Centre for Community Medicine, All India Institute of Medical Sciences (AIIMS) had claimed almost similar data.

Also Read | Gujarat Shocker: 40-Year-Old Teacher Raped By Online Friend in Ahmedabad; Accused Arrested.

Meanwhile, India's COVID-19 vaccination coverage has crossed 95 crores.

The nationwide vaccination drive started in India on January 16 with the healthcare workers (HCWs) and the frontline workers getting inoculated in the first phase.

Also Read | HP Chromebook x360 14a With AMD Processor Launched in India at Rs 32,999.

The next phase of COVID-19 vaccination commenced from March 1 for people over 60 years of age and those aged 45 and above with specified co-morbid conditions.

The country launched vaccination for all people aged more than 45 years from April 1.

The government then decided to expand its vaccination drive by allowing everyone above 18 to be vaccinated from May 1. (ANI)

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)